Lupin is currently trading at Rs. 874.25, up by 28.90 points or 3.42% from its previous closing of Rs. 845.35 on the BSE.
The scrip opened at Rs. 850.00 and has touched a high and low of Rs. 879.35 and Rs. 850.00 respectively. So far 404146 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1090.00 on 30-Oct-2017 and a 52 week low of Rs. 723.55 on 15-May-2018.
Last one week high and low of the scrip stood at Rs. 884.45 and Rs. 818.90 respectively. The current market cap of the company is Rs. 39616.68 crore.
The promoters holding in the company stood at 47.01%, while Institutions and Non-Institutions held 37.89% and 15.10% respectively.
Lupin has received tentative approval for its Lurasidone Hydrochloride Tablets, 20 mg, 40 mg, 60 mg, 80 mg and 120 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Sunovion Pharmaceuticals Inc.’s (Sunovion) Latuda Tablets, 20 mg, 40 mg, 60 mg, 80 mg and 120 mg.
Lupin’s Lurasidone Hydrochloride Tablets, 20 mg, 40 mg, 60 mg, 80 mg and 120 mg is the generic version of Sunovion’s Latuda Tablets, 20 mg, 40 mg, 60 mg, 80 mg and 120 mg. Lurasidone Hydrochloride Tablets, 20 mg, 40 mg, 60 mg, 80 mg and 120 mg had annual sales of around $3116 million in the US (IQVIA MAT June 2018).
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
